Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), commonly prescribed for type 2 diabetes and obesity, offer well-established systemic benefits; however, their long-term effects on ocular health remain unclear. To address this gap, a retrospective cohort study analyzed data to assess the risk of neovascular age-related macular degeneration (nAMD) associated with GLP-1 receptor agonist use in 139,002 older adults aged 66 years or older with diabetes. The study found that the incidence of neovascular age-related macular degeneration (nAMD) was higher in the GLP-1 RA–exposed group (0.2%) compared to the unexposed group (0.1%), with a difference of 0.1%.
The estimated hazard ratios for nAMD development were 2.11 in the unadjusted analysis and 2.21 in the adjusted analysis, indicating more than double the risk among patients receiving GLP-1 RAs. These findings suggest that GLP-1…
